Avalo Therapeutics, Inc.
NASDAQ:AVTXBiotechnology
Healthcare
$6.70 -2.18%
-$0.34 today
- Market cap
- $387.41M
- Beta
- 0.82
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$4.21
52W Low $4.50High $24.27
Volume 1.58M
Average 1.61M
Balance Sheet
Inspect the capital base behind the business.
Assets
$116.46M
FY 2025 · Annual
-22.7% YoYLiabilities
$33.41M
FY 2025 · Annual
+88.8% YoYEquity
$83.05M
FY 2025 · Annual
-37.6% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 54.59M | 13.17M | 7.42M | 134.55M | 15.86M |
| Short-term Investments | 0 | 0 | 0 | 0 | 82.48M |
| Net Receivables | 4.8M | 1.92M | 136K | 611K | 0 |
| Inventory | 38K | 20K | 0 | 0 | 0 |
| Other Current Assets | 51K | 1.31M | 844K | 3.73M | 6.95M |
| Total Current Assets | 61.85M | 16.42M | 8.4M | 138.89M | 105.29M |
| Property, Plant & Equipment (Net) | 2.7M | 2.41M | 1.97M | 1.21M | 460K |
| Goodwill | 14.41M | 14.41M | 10.5M | 10.5M | 10.5M |
| Intangible Assets | 38K | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.23M | 131K | 131K | 131K | 210K |
| Total Non-current Assets | 18.37M | 16.95M | 12.6M | 11.84M | 11.17M |
| Total Assets | 80.21M | 33.37M | 20.99M | 150.73M | 116.46M |
| Account Payables | 3.37M | 2.88M | 446K | 283K | 137K |
| Short-term Debt | 0 | 5.93M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 88K | 0 | 0 | 0 |
| Other Current Liabilities | 4.32M | 3.18M | 3.06M | 3.24M | 12.41M |
| Total Current Liabilities | 19.89M | 22.11M | 4.62M | 6.96M | 12.94M |
| Long-term Debt | 32.83M | 13.49M | 0 | 0 | 2M |
| Deferred Tax Liabilities | 113K | 141K | 155K | 270K | 434K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 4.3M | 8.54M | 8.92M | 10.47M | 18M |
| Total Non-current Liabilities | 37.24M | 22.17M | 9.07M | 10.74M | 20.47M |
| Total Liabilities | 57.13M | 44.28M | 13.69M | 17.7M | 33.41M |
| Common Stock | 9K | 0 | 1K | 10K | 18K |
| Retained Earnings | (262.17M) | (303.82M) | (335.13M) | (370.26M) | (448.52M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 68K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 23.08M | (10.92M) | 7.3M | 133.03M | 83.05M |
| Total Debt | 33.32M | 19.95M | 537K | 568K | 2.43M |
| Net Debt | (21.27M) | 6.78M | (6.88M) | (133.98M) | (13.43M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $25.0M |
| Short-term Investments | $57.0M |
| Other Current | $6.8M |
| Total Current Assets | $88.8M |
| PP&E (Net) | $375.0K |
| Goodwill | $10.5M |
| Other Non-current | $183.0K |
| Total Non-current Assets | $11.1M |
| Total Assets | $99.9M |
Analysis
Selected assets total $99.9M for Latest. The largest visible component is Short-term Investments at $57.0M, about 57.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| S-3ASR | S-3ASR filing | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 |
How much cash does AVTX have?
Avalo Therapeutics, Inc. (AVTX) reported $15.86M in cash and equivalents in fiscal 2025.
How much debt does AVTX carry?
Avalo Therapeutics, Inc. (AVTX) reported $2.43M of total debt, with net debt of -$13.43M.
Continue the stock analysis
Jump to another research area for this company.